Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma

HPB

Volumn 12, Issue 1, 2010, Pages 56-61

  McHugh, Patrick P ^a   Gilbert, Jeffrey ^a   Vera, Santiago ^b   Koch, Alvaro ^a   Ranjan, Dinesh ^a   Gedaly, Roberto ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Microvascular invasion

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GROUPS BY AGE; HISTOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; TUMOR VOLUME;

EID: 75449104468     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2009.00128.x     Document Type: Article

References (27)

1. Caldwell S, Park SH. (2009) The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 44 (Suppl. 19):96-101.
2. Penn I. (1991) Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 110:726-734.discussion 34-5.
3. Iwatsuki S, Gordon RD, Shaw BW, Jr, Starzl TE. (1985) Role of liver transplantation in cancer therapy. Ann Surg 202:401-407.
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693-699.
5. Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. (2001) Liver transplantation for hepatocellular carcinoma. Ann Surg 233:652-659.
6. Figueras J, Ibanez L, Ramos E, Jaurrieta E, Ortiz-De-Urbina J, Pardo F et al. (2001) Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl 7:877-883.
7. Broelsch CE, Frilling A, Malago M. (2004) Hepatoma - resection or transplantation. Surg Clin North Am 84:495-511.x.
8. Helton WS, Di Bisceglie A, Chari R, Schwartz M, Bruix J. (2003) Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 7:401-411.
9. Island ER, Pomposelli J, Pomfret EA, Gordon FD, Lewis WD, Jenkins RL. (2005) Twenty-year experience with liver transplantation for hepatocellular carcinoma. Arch Surg 140:353-358.
10. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I et al. (2005) Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 11:1086-1092.
11. Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W et al. (2004) Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 10:911-918.
12. Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T et al. (2001) Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33:1080-1086.
13. Colella G, De Carlis L, Rondinara GF, Sansalone CV, Belli LS, Aseni P et al. (1997) Is hepatocellular carcinoma in cirrhosis an actual indication for liver transplantation?Transplant Proc 29:492-494.
14. Tamura S, Kato T, Berho M, Misiakos EP, O'Brien C, Reddy KR et al. (2001) Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 136:25-30.discussion 1.
15. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A et al. (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394-1403.
16. Llovet JM, Bruix J. (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48 (Suppl. 1):S20-S37.
17. Iwatsuki S, Dvorchik I, Marsh JW, Madariaga JR, Carr B, Fung JJ et al. (2000) Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 191:389-394.
18. Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E et al. (2002) Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 50:123-128.
19. Olthoff KM, Rosove MH, Shackleton CR, Imagawa DK, Farmer DG, Northcross P et al. (1995) Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg 221:734-741.discussion 1-43.
20. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390.
21. Sotiropoulos GC, Malago M, Molmenti EP, Losch C, Lang H, Frilling A et al. (2007) Hilar lymph nodes sampling at the time of liver transplantation for hepatocellular carcinoma: to do or not to do? Meta-analysis to determine the impact of hilar lymph nodes metastases on tumor recurrence and survival in patients with hepatocellular carcinoma undergoing liver transplantation. Transpl Int 20:141-146.
22. Klintmalm GB. (1998) Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 228:479-490.
23. Marubashi S, Dono K, Sugita Y, Asaoka T, Hama N, Gotoh K et al. (2006) Alpha-fetoprotein mRNA detection in peripheral blood for prediction of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc 38:3640-3642.
24. Sakata J, Shirai Y, Wakai T, Kaneko K, Nagahashi M, Hatakeyama K. (2008) Preoperative predictors of vascular invasion in hepatocellular carcinoma. Eur J Surg Oncol 34:900-905.
25. Lohe F, Angele MK, Rentsch M, Graeb C, Gerbes A, Lohrs U et al. (2007) Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation. Clin Transplant 21:696-701.
26. Esnaola NF, Lauwers GY, Mirza NQ, Nagorney DM, Doherty D, Ikai I et al. (2002) Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 6:224-232.discussion 32.
27. Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S et al. (2008) Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 23:1541-1548.